Argenx
ARGX
#425
Rank
โ‚ฌ46.55 B
Marketcap
747,57ย โ‚ฌ
Share price
-1.30%
Change (1 day)
29.64%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): 7,75ย โ‚ฌ

According to Argenx 's latest financial reports the company's current EPS (TTM) is 7,55ย โ‚ฌ. In 2024 the company made an earnings per share (EPS) of 11,85ย โ‚ฌ an increase over its 2023 EPS that were of -4,39ย โ‚ฌ.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)7,75ย โ‚ฌ-34.61%
202411,85ย โ‚ฌ-369.77%
2023-4,39ย โ‚ฌ-60.46%
2022-11,11ย โ‚ฌ63.33%
2021-6,80ย โ‚ฌ-40.37%
2020-11,41ย โ‚ฌ183.47%
2019-4,03ย โ‚ฌ123.09%
2018-1,80ย โ‚ฌ54.93%
2017-1,16ย โ‚ฌ14.07%
2016-1,02ย โ‚ฌ13.05%
2015-0,90ย โ‚ฌ-36.34%
2014-1,42ย โ‚ฌ209.04%
2013-0,46ย โ‚ฌ-33.99%
2012-0,70ย โ‚ฌ185.59%
2011-0,24ย โ‚ฌ